

Meeting Notice

North Dakota Medicaid Drug Use Review Board

Wednesday, March 6th, 2024

1 to 4 p.m. Central Time

In-Person Information

Conference Room 210/212, 2nd Floor, Judicial Wing, State Capitol
600 E. Boulevard Ave., Bismarck

Virtual Information

Join virtually: [Click here to join the meeting](#)

Join by phone: 701-328-0950, Conference ID: 245 967 869 #

Agenda

1. Call to Order
2. Roll Call
3. Review and Approval of Minutes
4. Reports from Department
 - Administrative Report: COVID-19 treatment (Lagevrio & Paxlovid)
 - Financial Report: Budget, Top Drugs
 - Retrospective DUR Report
 - Clinical Report:
 - Prior authorization update
 - Criteria updates: Corticosteroids – Inhaled Criteria, Tardive Dyskinesia, Phenylketonuria
5. Unfinished business
 - Update to Hyperkalemia Criteria, Prophylaxis to Migraine, Eczema / Atopic Dermatitis, Cholestatic Pruritis
6. New business
 - First Review of Acid Blockers (Voquezna)
 - First Review of Seborrheic Dermatitis (Zoryve)
 - First Review of Primary Hyperoxaluria Type 1 (Rivfloza)
 - First Review of Myasthenia Gravis (Zilbrysq)
 - First Review of Duchenne Muscular Dystrophy (Emflaza, Agamree)
 - First Review of Paroxysmal Nocturnal Hemoglobinuria (Empaveli, Fabhalta)
 - Review of retrospective DUR criteria recommendations
7. Announcements
 - Next Meeting (June 5, 2024)
8. Adjourn

Individuals with disabilities who need accommodations, including appropriate auxiliary aids to participate, can contact Ashley Gerving at 701-328-2354, toll-free 800-755-2604, 711 (TTY) or gervingashley@nd.gov.